If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2015 09:14

RNS Number : 2142W
GW Pharmaceuticals PLC
17 August 2015
 



 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

119,050 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

72,150 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

46,900 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

200,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

122,613 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

312,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

755,473 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

56,978 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

800,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JANUARY 2015

500,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

208,550 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

2,800 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

205,750 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

168,650 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

784,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

1,021,408 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

763,043 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

1,000,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1223 266800

 

James Steel/Clare Terlouw, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRVDLBFEVFFBBX
Date   Source Headline
5th Mar 200710:12 amRNSDirector/PDMR Shareholding
28th Feb 20077:00 amRNSSativex Data Update
14th Feb 20077:01 amRNSAlliance with Otsuka
13th Feb 20079:53 amRNSResponse to speculation
30th Jan 20077:01 amRNSFinal Results
26th Jan 20077:00 amRNSBoard Appointment
24th Jan 20073:18 pmRNSHolding(s) in Company
17th Jan 20074:11 pmRNSTotal Voting Rights
15th Jan 20073:01 pmRNSNotice of Results
15th Jan 20077:01 amRNSResearch Update
18th Dec 20062:03 pmRNSTotal Voting Rights
26th Oct 20065:29 pmRNSBlocklisting Interim Review
19th Oct 20067:00 amRNSRegulatory Application
3rd Oct 20067:01 amRNSResearch Update
28th Sep 20067:00 amRNSSite Visit
5th Sep 20067:00 amRNSSativex filing
9th Aug 20067:00 amRNSResearch Update
21st Jul 20064:17 pmRNSDirector/PDMR Shareholding
20th Jun 20067:01 amRNSInterim Results
25th May 20061:37 pmRNSNotice of Results and R&D Day
19th May 20065:20 pmRNSDirector/PDMR Shareholding
16th May 20064:19 pmRNSHolding(s) in Company
16th May 20067:00 amRNSAppointment of Adviser
27th Apr 200612:45 pmRNSBlocklisting Interim Review
24th Mar 20063:33 pmRNSDirector/PDMR Shareholding
21st Mar 20062:36 pmRNSAGM Statement
17th Mar 20067:03 amRNSResearch Update
13th Feb 20067:01 amRNSGrant of Share Options
19th Jan 20067:01 amRNSFinal Results
11th Jan 20064:11 pmRNSHolding(s) in Company
4th Jan 200612:39 pmRNSAdditional Listing
4th Jan 20067:03 amRNSUS Placing
4th Jan 20067:00 amRNSFDA Accepts IND Application
16th Dec 20053:14 pmRNSRe Inquest Verdict
14th Dec 200510:20 amRNSNotice of Results
12th Dec 20057:01 amRNSMarketing Agreement
15th Nov 20057:02 amRNSRe Sativex Update
11th Nov 20053:22 pmRNSBlocklisting Interim Review
9th Nov 20057:01 amRNSSativex - Peer Review
8th Nov 20057:02 amRNSSativex - Supplied in Spain
27th Sep 20057:04 amRNSSativex - Peer Review
1st Sep 200511:14 amRNSAdditional Listing
21st Jul 20053:28 pmRNSAdditional Listing
20th Jun 20057:02 amRNSSativex Launch Canada
20th Jun 20057:01 amRNSInterim Results
10th Jun 20057:00 amRNSUK Regulatory Update
6th Jun 20056:19 pmRNSStatement re. Press Comment
1st Jun 20053:26 pmRNSHolding(s) in Company
26th May 20052:49 pmRNSNotice of Results
11th May 20057:00 amRNSRe Marketing Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.